Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2Unknown 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Genitourinary 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 18Breast Neoplasms 17Advanced Solid Tumors 16Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Myelodysplastic Syndromes 8Solid Tumor 6Recurrence 6Prostatic Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Ovarian Neoplasms 5Carcinoma, Hepatocellular 5Small Cell Lung Carcinoma 4Myeloproliferative Disorders 4Multiple Myeloma 4Advanced Solid Tumour 4Advanced Malignant Solid Tumor 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Biliary Tract Neoplasms 3Advanced Lung Cancer 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2

Interventions

lutetium Lu 177 dotatate 10Everolimus 5lanreotide 4gallium Ga 68 dotatate 4Nivolumab 4Magnetic Resonance Spectroscopy 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4olaparib 3Temozolomide 3Somatostatin 3Capecitabine 3surufatinib 2pembrolizumab 2copper dotatate CU-64 2cabozantinib 2amino-acid, glucose, and electrolyte solution 2Specimen Handling 2Octreotide 2Lutetium-177 2Lutetium 2Injections 2Fluorodeoxyglucose F18 2Cyclophosphamide 2tivozanib 1talazoparib 1sintilimab 1repotrectinib 1lenvatinib 1guarana powder 1gadoteridol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neuroendocrine Tumors × Injections × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT04837885 2025-07-23

LUTARTERIAL

University Hospital, Bordeaux

Phase 2 Recruiting
23 enrolled
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡